Advanced Prostate – Call For Grant (2) - Optimizing Treatment Outcomes in mCSPC; Evolving Evidence and Clinical Trial Design
Bayer funds educational projects to advance treatment strategies and clinical trial innovations in metastatic hormone-sensitive prostate cancer (mHSPC).
Funder: Bayer
Due Dates: Rolling (monthly review; allow minimum 45 days for response)
Funding Amounts: Amount not specified; budget required in proposal; typical for educational grants.
Summary: Supports educational initiatives to optimize treatment outcomes and advance clinical trial design in metastatic hormone-sensitive prostate cancer (mHSPC).
Key Information: Proposals must comply with standards for commercial support (e.g., ACCME) and include detailed educational design and budget.
Description
This grant opportunity, offered by Bayer, aims to fund educational projects that address the latest advancements in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The focus includes integrating biomarker- and imaging-selected approaches, evaluating new doublet and triplet systemic regimens, and tackling evidence gaps and recruitment challenges in clinical trials. The grant encourages the exploration of novel and pragmatic clinical trial designs, such as those using historical/external comparators and AI-enabled methods, to improve trial efficiency and generalizability. The overarching goal is to enhance the practical application of new evidence and address clinical questions that are difficult or infeasible with traditional trial methods.
